CLINICAL_TRIALS
trial_result
· 2015-02-12
Clinical Trial Update: Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC [Phase 3]
Summary
This entry reports a Phase 3 clinical trial investigating erlotinib at 100 mg or 150 mg in patients with EGFR-mutated non-small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: NSCLC, EGFR Mutation | Phase 3 | Status: UNKNOWN